37.48
Harrow Inc stock is traded at $37.48, with a volume of 1.11M.
It is down -7.62% in the last 24 hours and down -3.58% over the past month.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
See More
Previous Close:
$40.57
Open:
$40.75
24h Volume:
1.11M
Relative Volume:
1.63
Market Cap:
$1.39B
Revenue:
$154.15M
Net Income/Loss:
$-33.58M
P/E Ratio:
-39.04
EPS:
-0.96
Net Cash Flow:
$-20.74M
1W Performance:
-17.50%
1M Performance:
-3.58%
6M Performance:
+59.66%
1Y Performance:
-24.54%
Harrow Inc Stock (HROW) Company Profile
Name
Harrow Inc
Sector
Phone
615.733.4731
Address
1A BURTON HILLS BLVD, NASHVILLE, CA
Compare HROW with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
HROW
Harrow Inc
|
37.48 | 1.50B | 154.15M | -33.58M | -20.74M | -0.96 |
![]()
ZTS
Zoetis Inc
|
141.11 | 63.55B | 9.39B | 2.62B | 2.22B | 5.8121 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
13.71 | 44.47B | 29.96B | 957.25M | 4.77B | 0.2956 |
![]()
HLN
Haleon Plc Adr
|
9.00 | 40.17B | 14.26B | 1.98B | 2.47B | 0.4327 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.03 | 22.99B | 16.70B | -157.13M | 1.19B | -0.1446 |
![]()
UTHR
United Therapeutics Corp
|
440.00 | 20.14B | 3.08B | 1.24B | 1.07B | 25.61 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
Jun-12-25 | Initiated | BTIG Research | Buy |
Jun-10-25 | Initiated | William Blair | Outperform |
Feb-06-25 | Initiated | H.C. Wainwright | Buy |
Dec-04-24 | Reiterated | B. Riley Securities | Buy |
Apr-11-24 | Initiated | Craig Hallum | Buy |
Sep-08-22 | Resumed | B. Riley Securities | Buy |
Oct-14-21 | Resumed | B. Riley Securities | Buy |
Sep-24-21 | Initiated | Aegis Capital | Buy |
Jul-02-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Harrow Inc Stock (HROW) Latest News
Is it too late to sell Harrow Inc.Earnings Growth Report & Real-Time Chart Breakout Alerts - newser.com
What data driven models say about Harrow Inc.’s futurePortfolio Risk Report & Weekly High Conviction Trade Ideas - newser.com
What institutional flow reveals about Harrow Inc.Dollar Strength & Entry and Exit Point Strategies - newser.com
Using data tools to time your Harrow Inc. exitJuly 2025 Movers & Weekly Chart Analysis and Guides - newser.com
Weiss Ratings Reaffirms Sell (E+) Rating for Harrow (NASDAQ:HROW) - MarketBeat
Harrow, Inc. (HROW): A Bull Case Theory - Insider Monkey
Will Harrow's (HROW) Affordability Push and New Leadership Shift its Long-Term Growth Trajectory? - simplywall.st
Could Harrow’s (HROW) New Pricing Program Redefine Its Patient Access Advantage? - Yahoo Finance
ImprimisRx Announces Leadership Changes - GlobeNewswire
Is Harrow Inc. stock dividend yield sustainableWeekly Profit Analysis & Daily Chart Pattern Signal Reports - newser.com
Harrow names Frank Mullery as CEO of ImprimisRx subsidiary - Investing.com
Harrow Health (HROW) Appoints New Leadership at ImprimisRx - GuruFocus
Harrow Health Announces New Leadership at ImprimisRx - TipRanks
Harrow names Frank Mullery as CEO of ImprimisRx subsidiary By Investing.com - Investing.com Canada
ImprimisRx announces leadership changes - MarketScreener
Leadership Appointments at ImprimisRx: Frank Mullery Named CEO and Bridseida Cruz as Head of Quality - Quiver Quantitative
Frank Mullery named CEO; Bridseida Cruz named Head of Quality at ImprimisRx, Harrow subsidiary - Stock Titan
Intraday pattern recognizer results for Harrow Inc.Bull Run & Technical Pattern Recognition Alerts - newser.com
How to escape a deep drawdown in Harrow Inc.July 2025 Sector Moves & Fast Exit Strategy with Risk Control - newser.com
Assessing Harrow’s Value After a 22.8% Surge and Recent Earnings Release - simplywall.st
How to track smart money flows in Harrow Inc.Market Volume Report & Smart Money Movement Alerts - newser.com
Harrow (NASDAQ:HROW) Trading Down 4.9%Should You Sell? - MarketBeat
A Fresh Look at Harrow (HROW) Valuation Following Recent Share Price Momentum - simplywall.st
Harrow, Inc. (NASDAQ:HROW) Looks Just Right With A 27% Price Jump - simplywall.st
Research Analysts Issue Forecasts for Harrow Q3 Earnings - MarketBeat
How to use Fibonacci retracement on Harrow Inc.2025 Top Gainers & High Yield Stock Recommendations - newser.com
B. Riley Comments on Harrow's Q4 Earnings (NASDAQ:HROW) - MarketBeat
Harrow announces leadership changes, Andrew Boll to serve as President and CFO - MSN
B. Riley Securities Reiterates Harrow (HROW) Buy Recommendation - Nasdaq
HROW: B. Riley Securities Increases Price Target to $74, Reitera - GuruFocus
Harrow to purchase Melt Pharmaceuticals - Eyes On Eyecare
B. Riley Adjusts Price Target on Harrow to $74 From $70, Maintains Buy Rating - MarketScreener
William Blair Issues Positive Outlook for Harrow Earnings - MarketBeat
What is William Blair's Estimate for Harrow FY2025 Earnings? - MarketBeat
Lake Street Maintains Harrow (HROW) Buy Recommendation - Nasdaq
Harrow (NASDAQ:HROW) Shares Gap UpStill a Buy? - MarketBeat
HROW Analyst Update: Lake Street Raises Price Target to $70 | HR - GuruFocus
H.C. Wainwright reiterates Buy rating on Harrow Health stock, maintains $64 target - Investing.com Australia
HC Wainwright Reaffirms Buy Rating for Harrow (NASDAQ:HROW) - MarketBeat
Harrow Inc Stock (HROW) Financials Data
Revenue
Net Income
Cash Flow
EPS
Harrow Inc Stock (HROW) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Opaleye Management Inc. | 10% Owner |
Jun 10 '25 |
Sale |
30.80 |
15,000 |
462,033 |
90,000 |
Opaleye Management Inc. | 10% Owner |
Jun 09 '25 |
Sale |
30.37 |
15,204 |
461,794 |
105,000 |
Opaleye Management Inc. | 10% Owner |
Jun 03 '25 |
Sale |
30.04 |
3,000 |
90,116 |
122,000 |
Opaleye Management Inc. | 10% Owner |
Jun 04 '25 |
Sale |
30.02 |
1,796 |
53,907 |
120,204 |
Opaleye Management Inc. | 10% Owner |
May 12 '25 |
Sale |
25.90 |
10,000 |
258,959 |
130,000 |
Opaleye Management Inc. | 10% Owner |
May 13 '25 |
Sale |
26.59 |
5,000 |
132,945 |
125,000 |
BOLL ANDREW R. | Chief Financial Officer |
Apr 03 '25 |
Option Exercise |
0.00 |
346,500 |
0 |
914,589 |
SAHAREK JOHN P. | CEO & President, ImprimisRx |
Apr 03 '25 |
Option Exercise |
0.00 |
277,200 |
0 |
576,863 |
BAUM MARK L | Chief Executive Officer |
Apr 03 '25 |
Option Exercise |
0.00 |
762,300 |
0 |
2,899,825 |
Opaleye Management Inc. | 10% Owner |
Mar 18 '25 |
Sale |
30.01 |
5,000 |
150,055 |
140,000 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):